| . | AHD . | Rest of population . | P-value . |
|---|---|---|---|
| Male | 92.3% | 87.1% | 0.58 |
| Age (years) | 66.6 ± 12.4 | 63.4 ± 13 | 0.38 |
| Ischaemic cardiomyopathy | 76.9% | 66.7% | 0.44 |
| Dilated cardiomyopathy | 23.1% | 17.8% | 0.62 |
| Arterial hypertension | 69.2% | 66.4% | 0.83 |
| Congestive heart failure | 100% | 92.7% | 0.46 |
| NYHA Class | 2.8 ± 0.6 | 2.0 ± 1.0 | 0.01 |
| Diabetes mellitus | 23.1% | 31,4% | 0.52 |
| Stroke/transient ischaemic attack | 30.8% | 11,3% | 0.03 |
| Coronary (or peripheral) artery disease | 84.6% | 68.2% | 0.21 |
| CHA2DS2-VASc score | 4.3 ± 1.5 | 3.6 ± 1.7 | 0.28 |
| Chronic obstructive pulmonary disease | 15.4% | 11.6% | 0.67 |
| Serum creatinine (µmol/L) | 136.9 ± 56.3 | 112.2 ± 47.9 | 0.07 |
| Left ventricular ejection fraction (%) | 27.6 ± 9.3 | 34.2 ± 12.5 | 0.08 |
| Electrical storm | 61.5% | 24.3% | 0.002 |
| PAINESD score | 14.9 ± 5.6 | 11.4 ± 6.6 | 0.05 |
| Procedure time (min) | 171 ± 38 | 189 ± 60 | 0.34 |
| General anaesthesia (%) | 23.1% | 15.0% | 0.42 |
| Radiofrequency time (min) | 27.6 ± 15.8 | 22.7 ± 15.5 | 0.31 |
| Re-ablation during follow-up | 23.1% | 28.4% | 0.67 |
| MCS during follow-up | 23.1% | 3.3% | 0.0001 |
| Heart transplant during follow-up | 0.0% | 4.6% | 0.43 |
| Death | 76.9% | 47.6% | 0.04 |
| . | AHD . | Rest of population . | P-value . |
|---|---|---|---|
| Male | 92.3% | 87.1% | 0.58 |
| Age (years) | 66.6 ± 12.4 | 63.4 ± 13 | 0.38 |
| Ischaemic cardiomyopathy | 76.9% | 66.7% | 0.44 |
| Dilated cardiomyopathy | 23.1% | 17.8% | 0.62 |
| Arterial hypertension | 69.2% | 66.4% | 0.83 |
| Congestive heart failure | 100% | 92.7% | 0.46 |
| NYHA Class | 2.8 ± 0.6 | 2.0 ± 1.0 | 0.01 |
| Diabetes mellitus | 23.1% | 31,4% | 0.52 |
| Stroke/transient ischaemic attack | 30.8% | 11,3% | 0.03 |
| Coronary (or peripheral) artery disease | 84.6% | 68.2% | 0.21 |
| CHA2DS2-VASc score | 4.3 ± 1.5 | 3.6 ± 1.7 | 0.28 |
| Chronic obstructive pulmonary disease | 15.4% | 11.6% | 0.67 |
| Serum creatinine (µmol/L) | 136.9 ± 56.3 | 112.2 ± 47.9 | 0.07 |
| Left ventricular ejection fraction (%) | 27.6 ± 9.3 | 34.2 ± 12.5 | 0.08 |
| Electrical storm | 61.5% | 24.3% | 0.002 |
| PAINESD score | 14.9 ± 5.6 | 11.4 ± 6.6 | 0.05 |
| Procedure time (min) | 171 ± 38 | 189 ± 60 | 0.34 |
| General anaesthesia (%) | 23.1% | 15.0% | 0.42 |
| Radiofrequency time (min) | 27.6 ± 15.8 | 22.7 ± 15.5 | 0.31 |
| Re-ablation during follow-up | 23.1% | 28.4% | 0.67 |
| MCS during follow-up | 23.1% | 3.3% | 0.0001 |
| Heart transplant during follow-up | 0.0% | 4.6% | 0.43 |
| Death | 76.9% | 47.6% | 0.04 |
Data are provided as means ± SD or counts (proportions).
AHD, acute haemodynamic decompensation; MCS, mechanical circulatory support; NYHA, New York Heart Association.
| . | AHD . | Rest of population . | P-value . |
|---|---|---|---|
| Male | 92.3% | 87.1% | 0.58 |
| Age (years) | 66.6 ± 12.4 | 63.4 ± 13 | 0.38 |
| Ischaemic cardiomyopathy | 76.9% | 66.7% | 0.44 |
| Dilated cardiomyopathy | 23.1% | 17.8% | 0.62 |
| Arterial hypertension | 69.2% | 66.4% | 0.83 |
| Congestive heart failure | 100% | 92.7% | 0.46 |
| NYHA Class | 2.8 ± 0.6 | 2.0 ± 1.0 | 0.01 |
| Diabetes mellitus | 23.1% | 31,4% | 0.52 |
| Stroke/transient ischaemic attack | 30.8% | 11,3% | 0.03 |
| Coronary (or peripheral) artery disease | 84.6% | 68.2% | 0.21 |
| CHA2DS2-VASc score | 4.3 ± 1.5 | 3.6 ± 1.7 | 0.28 |
| Chronic obstructive pulmonary disease | 15.4% | 11.6% | 0.67 |
| Serum creatinine (µmol/L) | 136.9 ± 56.3 | 112.2 ± 47.9 | 0.07 |
| Left ventricular ejection fraction (%) | 27.6 ± 9.3 | 34.2 ± 12.5 | 0.08 |
| Electrical storm | 61.5% | 24.3% | 0.002 |
| PAINESD score | 14.9 ± 5.6 | 11.4 ± 6.6 | 0.05 |
| Procedure time (min) | 171 ± 38 | 189 ± 60 | 0.34 |
| General anaesthesia (%) | 23.1% | 15.0% | 0.42 |
| Radiofrequency time (min) | 27.6 ± 15.8 | 22.7 ± 15.5 | 0.31 |
| Re-ablation during follow-up | 23.1% | 28.4% | 0.67 |
| MCS during follow-up | 23.1% | 3.3% | 0.0001 |
| Heart transplant during follow-up | 0.0% | 4.6% | 0.43 |
| Death | 76.9% | 47.6% | 0.04 |
| . | AHD . | Rest of population . | P-value . |
|---|---|---|---|
| Male | 92.3% | 87.1% | 0.58 |
| Age (years) | 66.6 ± 12.4 | 63.4 ± 13 | 0.38 |
| Ischaemic cardiomyopathy | 76.9% | 66.7% | 0.44 |
| Dilated cardiomyopathy | 23.1% | 17.8% | 0.62 |
| Arterial hypertension | 69.2% | 66.4% | 0.83 |
| Congestive heart failure | 100% | 92.7% | 0.46 |
| NYHA Class | 2.8 ± 0.6 | 2.0 ± 1.0 | 0.01 |
| Diabetes mellitus | 23.1% | 31,4% | 0.52 |
| Stroke/transient ischaemic attack | 30.8% | 11,3% | 0.03 |
| Coronary (or peripheral) artery disease | 84.6% | 68.2% | 0.21 |
| CHA2DS2-VASc score | 4.3 ± 1.5 | 3.6 ± 1.7 | 0.28 |
| Chronic obstructive pulmonary disease | 15.4% | 11.6% | 0.67 |
| Serum creatinine (µmol/L) | 136.9 ± 56.3 | 112.2 ± 47.9 | 0.07 |
| Left ventricular ejection fraction (%) | 27.6 ± 9.3 | 34.2 ± 12.5 | 0.08 |
| Electrical storm | 61.5% | 24.3% | 0.002 |
| PAINESD score | 14.9 ± 5.6 | 11.4 ± 6.6 | 0.05 |
| Procedure time (min) | 171 ± 38 | 189 ± 60 | 0.34 |
| General anaesthesia (%) | 23.1% | 15.0% | 0.42 |
| Radiofrequency time (min) | 27.6 ± 15.8 | 22.7 ± 15.5 | 0.31 |
| Re-ablation during follow-up | 23.1% | 28.4% | 0.67 |
| MCS during follow-up | 23.1% | 3.3% | 0.0001 |
| Heart transplant during follow-up | 0.0% | 4.6% | 0.43 |
| Death | 76.9% | 47.6% | 0.04 |
Data are provided as means ± SD or counts (proportions).
AHD, acute haemodynamic decompensation; MCS, mechanical circulatory support; NYHA, New York Heart Association.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
